Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications 

Summary by AI BETAClose X

Centessa Pharmaceuticals announced a CEO transition effective January 1, 2026, with Mario Alberto Accardi PhD appointed as the new Chief Executive Officer and Board member, succeeding Saurabh Saha MD PhD. This change aligns with the company's strategic focus on advancing its pure-play orexin portfolio for multiple neuroscience indications. Dr. Accardi, founder of Centessa’s Orexin Program, will lead the development of OX2R agonists, including ORX750 for narcolepsy and idiopathic hypersomnia, with a registrational program expected in Q1 2026, and ORX142 and ORX489 targeting neurodegenerative and neuropsychiatric disorders, with key milestones anticipated in 2026.

Disclaimer*

UK 100

Latest directors dealings